These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26653034)

  • 21. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB; Lund-Andersen H; Sander B; Larsen M
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
    Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
    Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Presence of Intra- or Subretinal Fluid during the Loading Phase in the Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab Assessed by Optical Coherence Tomography.
    Ebneter A; Gekkiev B; Chanana B; Wolf S; Zinkernagel MS
    Ophthalmologica; 2015; 234(2):61-6. PubMed ID: 25998752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
    Flaxel C; Schain MB; Hamon SC; Francis PJ
    Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.
    Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ
    Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
    Querques G; Querques L; Rafaeli O; Canoui-Poitrine F; Bandello F; Souied EH
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):7012-8. PubMed ID: 21885622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
    Wickremasinghe SS; Guymer RH; Wong TY; Kawasaki R; Wong W; Qureshi S
    Clin Exp Ophthalmol; 2012; 40(1):59-66. PubMed ID: 21668787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.